Five Types of Fatty Liver Disease Revealed

Study identifies distinct genetic and clinical profiles that could improve risk assessment and personalize care for patients with fatty liver disease

November 10, 2026
2 min

The Pathologist

At a Glance

Category	Detail
Condition	Metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH)
Key Mechanisms	Five subgroups were identified with distinct metabolic, genetic, and disease-risk profiles; variants in TM6SF2, MBOAT7, and HSD17B13 were associated with elevated liver-transplant risk in one subgroup.
Target Population	Patients with MASLD represented in two Mayo Clinic research cohorts.
Care Setting	Clinical risk classification and monitoring context; the proposed subtypes require further validation before routine clinical use.

Key Highlights

Researchers identified five MASLD subgroups using clinical characteristics and genomic information; the patterns were reproduced in an independent cohort.
Two subgroups had substantial metabolic disease and high rates of type 2 diabetes and sleep apnea, with differing associated risks and characteristics.
A subgroup with relatively few metabolic complications had the highest overall rate of liver transplantation and genetic associations involving TM6SF2, MBOAT7, and HSD17B13.
A MASH-characterized, genetically influenced subgroup had increased risks of advanced liver fibrosis and acute kidney failure.
The study was observational; the proposed subtypes require further validation before informing routine clinical decisions.

Guideline-Based Recommendations

Diagnosis

The study used statistical analysis of clinical characteristics and genomic information to identify five subgroups; it does not establish a routine diagnostic method.

Management

The article describes potential value in integrating genomic risk profiles with routine clinical information, but does not provide treatment recommendations.

Monitoring & Follow-up

The researchers describe potential use of the subtypes to identify patients requiring closer monitoring and refine surveillance strategies; these applications require further validation.

Risks

Conventional metabolic risk indicators alone may fail to identify patients at greatest risk of severe liver disease.
Reported subgroup risks included cardiovascular and kidney-related risks, advanced liver fibrosis, acute kidney failure, and liver transplantation.

Patient & Prescribing Data

The study analyzed two Mayo Clinic research cohorts of patients with MASLD; the article does not report prescribing data.

No specific treatments or prescribing recommendations are reported. Tailored treatments are described as a potential future application of understanding subgroup biology.

Clinical Best Practices

The study reports that conventional metabolic risk indicators alone may fail to identify patients at greatest risk of severe liver disease.
Interpret the proposed MASLD subtypes as research findings rather than established routine clinical categories.
Further validation is needed before using the proposed subtypes to guide routine clinical decisions.